ABL Diagnostics Société anonyme (ABLD) Fair Value & Analysis
Healthcare · FR · Market cap €55.0M
Fair value as of: Jun 24, 2026
Analysis
ABL Diagnostics Société anonyme (ABLD) currently trades at €2.58, while our model-based Fair Value estimate is €1.04 — implying the stock looks roughly 59.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is ABL Diagnostics Société anonyme (ABLD) undervalued?
What is the fair value of ABLD?
What is the quality score of ABLD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.